Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hirsutism | 4 | 2018 | 68 | 1.070 |
Why?
|
| Gonadotropin-Releasing Hormone | 20 | 2021 | 1153 | 0.990 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2010 | 1206 | 0.670 |
Why?
|
| Amenorrhea | 8 | 2021 | 480 | 0.630 |
Why?
|
| Hair Removal | 1 | 2018 | 40 | 0.590 |
Why?
|
| Hypothalamic Diseases | 4 | 2021 | 134 | 0.590 |
Why?
|
| Luteinizing Hormone | 21 | 2011 | 820 | 0.580 |
Why?
|
| Neurosecretory Systems | 5 | 2013 | 221 | 0.480 |
Why?
|
| Follicle Stimulating Hormone | 21 | 2011 | 725 | 0.420 |
Why?
|
| Receptors, LHRH | 9 | 2011 | 158 | 0.380 |
Why?
|
| Hypogonadism | 10 | 2021 | 801 | 0.370 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 250 | 0.370 |
Why?
|
| Polycystic Ovary Syndrome | 8 | 2024 | 377 | 0.360 |
Why?
|
| Hot Flashes | 3 | 2008 | 328 | 0.350 |
Why?
|
| Estradiol | 13 | 2006 | 1932 | 0.340 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 5 | 2008 | 95 | 0.320 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2018 | 116 | 0.290 |
Why?
|
| Postmenopause | 5 | 2006 | 2509 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 4 | 2024 | 7475 | 0.250 |
Why?
|
| Inhibins | 6 | 2005 | 209 | 0.220 |
Why?
|
| Endocrinology | 3 | 2016 | 443 | 0.210 |
Why?
|
| Androgens | 4 | 2018 | 1291 | 0.200 |
Why?
|
| Evidence-Based Medicine | 3 | 2024 | 3696 | 0.200 |
Why?
|
| Menopause | 2 | 2008 | 1640 | 0.200 |
Why?
|
| Menstruation | 2 | 2011 | 307 | 0.190 |
Why?
|
| Ovulation Induction | 6 | 2001 | 277 | 0.190 |
Why?
|
| Activity Cycles | 1 | 2000 | 47 | 0.180 |
Why?
|
| Leuprolide | 2 | 2001 | 315 | 0.170 |
Why?
|
| Premenopause | 2 | 2018 | 1038 | 0.170 |
Why?
|
| Luteal Phase | 6 | 1998 | 138 | 0.160 |
Why?
|
| Progesterone | 9 | 2005 | 742 | 0.160 |
Why?
|
| Androgen Antagonists | 2 | 2018 | 1442 | 0.160 |
Why?
|
| Hormone Replacement Therapy | 2 | 2016 | 755 | 0.160 |
Why?
|
| Menstrual Cycle | 4 | 1998 | 536 | 0.160 |
Why?
|
| Gonadotropins | 2 | 2002 | 241 | 0.150 |
Why?
|
| Reproductive Medicine | 1 | 1999 | 100 | 0.150 |
Why?
|
| Chorionic Gonadotropin | 4 | 2008 | 457 | 0.130 |
Why?
|
| Administration, Cutaneous | 2 | 2008 | 713 | 0.120 |
Why?
|
| Neurotransmitter Agents | 1 | 1999 | 663 | 0.120 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 3149 | 0.120 |
Why?
|
| Drug Compounding | 1 | 2016 | 246 | 0.120 |
Why?
|
| Follicular Phase | 5 | 1997 | 143 | 0.120 |
Why?
|
| Embryo Transfer | 1 | 1997 | 522 | 0.110 |
Why?
|
| Pituitary Gland | 3 | 2013 | 637 | 0.110 |
Why?
|
| Fertilization in Vitro | 2 | 2001 | 1292 | 0.110 |
Why?
|
| Hormones | 1 | 2016 | 867 | 0.100 |
Why?
|
| Fertility Agents, Female | 2 | 2001 | 101 | 0.090 |
Why?
|
| Heterozygote | 4 | 2011 | 2798 | 0.090 |
Why?
|
| Female | 49 | 2024 | 391246 | 0.090 |
Why?
|
| Estrogens | 2 | 2008 | 1520 | 0.090 |
Why?
|
| Ovarian Diseases | 1 | 1990 | 137 | 0.080 |
Why?
|
| Information Literacy | 1 | 2009 | 11 | 0.080 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2008 | 25 | 0.080 |
Why?
|
| Ovary | 5 | 2011 | 958 | 0.080 |
Why?
|
| Azoospermia | 1 | 2008 | 28 | 0.080 |
Why?
|
| Administration, Intravaginal | 1 | 2008 | 151 | 0.080 |
Why?
|
| Cognition | 1 | 2006 | 6964 | 0.080 |
Why?
|
| Reproduction | 1 | 2013 | 646 | 0.080 |
Why?
|
| Periodicity | 4 | 1998 | 348 | 0.070 |
Why?
|
| Spermatogenesis | 1 | 2008 | 257 | 0.070 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2008 | 190 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 302 | 0.070 |
Why?
|
| Humans | 53 | 2024 | 760613 | 0.070 |
Why?
|
| Mass Media | 1 | 2009 | 300 | 0.070 |
Why?
|
| Ovulation | 4 | 2001 | 181 | 0.060 |
Why?
|
| Theca Cells | 1 | 2005 | 15 | 0.060 |
Why?
|
| Oophoritis | 1 | 2005 | 4 | 0.060 |
Why?
|
| School Health Services | 1 | 2009 | 382 | 0.060 |
Why?
|
| Perimenopause | 1 | 2006 | 141 | 0.060 |
Why?
|
| Adult | 33 | 2021 | 220007 | 0.060 |
Why?
|
| Ovarian Follicle | 2 | 2005 | 244 | 0.060 |
Why?
|
| Gonadal Steroid Hormones | 3 | 1997 | 701 | 0.060 |
Why?
|
| Atrophy | 1 | 2008 | 1626 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2011 | 1245 | 0.050 |
Why?
|
| Vagina | 1 | 2008 | 837 | 0.050 |
Why?
|
| Violence | 1 | 2009 | 927 | 0.050 |
Why?
|
| Mutation | 6 | 2013 | 29957 | 0.050 |
Why?
|
| Adolescent | 19 | 2021 | 87809 | 0.050 |
Why?
|
| Hormone Antagonists | 2 | 1999 | 108 | 0.050 |
Why?
|
| Aging | 1 | 2000 | 8652 | 0.050 |
Why?
|
| Follicular Fluid | 1 | 2001 | 92 | 0.050 |
Why?
|
| Pregnancy | 9 | 2001 | 29746 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 15840 | 0.040 |
Why?
|
| Institutional Practice | 1 | 1999 | 16 | 0.040 |
Why?
|
| Phenotype | 4 | 2011 | 16548 | 0.040 |
Why?
|
| Metoclopramide | 1 | 1999 | 51 | 0.040 |
Why?
|
| Dipeptides | 2 | 1999 | 410 | 0.040 |
Why?
|
| Estrone | 1 | 2000 | 232 | 0.040 |
Why?
|
| Sleep Deprivation | 1 | 2006 | 840 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 361 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1999 | 178 | 0.040 |
Why?
|
| Clonidine | 1 | 1999 | 170 | 0.040 |
Why?
|
| Dopamine Antagonists | 1 | 1999 | 288 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2001 | 393 | 0.040 |
Why?
|
| Hypothalamus | 2 | 1994 | 998 | 0.040 |
Why?
|
| Middle Aged | 11 | 2021 | 220359 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2021 | 3613 | 0.040 |
Why?
|
| Protein Precursors | 2 | 2011 | 1134 | 0.030 |
Why?
|
| Health Promotion | 1 | 2009 | 2207 | 0.030 |
Why?
|
| Naloxone | 1 | 1999 | 369 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2011 | 829 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 788 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2006 | 2212 | 0.030 |
Why?
|
| Syndrome | 1 | 2001 | 3280 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 221 | 0.030 |
Why?
|
| Hospitals, General | 1 | 1999 | 795 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2001 | 1016 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 1999 | 583 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2001 | 14494 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 6498 | 0.030 |
Why?
|
| Pulsatile Flow | 3 | 2001 | 321 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 12968 | 0.030 |
Why?
|
| Infertility, Female | 1 | 1999 | 759 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2006 | 7022 | 0.030 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 1993 | 47 | 0.030 |
Why?
|
| Genotype | 3 | 2013 | 12957 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2005 | 2250 | 0.030 |
Why?
|
| Pregnancy, Multiple | 1 | 1993 | 215 | 0.030 |
Why?
|
| Insulin | 3 | 2002 | 6596 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 4108 | 0.030 |
Why?
|
| Receptors, FSH | 1 | 1991 | 29 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2006 | 12427 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2001 | 1357 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 8055 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2021 | 2567 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 2716 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2001 | 2985 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2013 | 64981 | 0.020 |
Why?
|
| Research | 1 | 1999 | 1974 | 0.020 |
Why?
|
| Body Mass Index | 4 | 2002 | 12914 | 0.020 |
Why?
|
| Reference Values | 4 | 2002 | 4925 | 0.020 |
Why?
|
| Semen | 1 | 1993 | 346 | 0.020 |
Why?
|
| Weight Loss | 1 | 2001 | 2684 | 0.020 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 1 | 1989 | 36 | 0.020 |
Why?
|
| Fertility | 1 | 1994 | 773 | 0.020 |
Why?
|
| Infertility, Male | 1 | 1993 | 396 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2011 | 256 | 0.020 |
Why?
|
| Receptors, Peptide | 1 | 2011 | 279 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1989 | 163 | 0.020 |
Why?
|
| Amino Acid Sequence | 4 | 2004 | 13451 | 0.020 |
Why?
|
| Lipoproteins | 1 | 1993 | 882 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 4408 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 10826 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1992 | 699 | 0.020 |
Why?
|
| DNA | 3 | 2011 | 7233 | 0.020 |
Why?
|
| Sperm Motility | 1 | 2008 | 265 | 0.020 |
Why?
|
| Testosterone | 3 | 2008 | 2470 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 3802 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2021 | 22052 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 2392 | 0.020 |
Why?
|
| Feedback | 1 | 1990 | 791 | 0.020 |
Why?
|
| Base Sequence | 3 | 2004 | 12444 | 0.020 |
Why?
|
| Women's Health | 1 | 2016 | 2056 | 0.020 |
Why?
|
| Aged | 5 | 2021 | 169143 | 0.020 |
Why?
|
| Massachusetts | 1 | 1999 | 8803 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2001 | 4446 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 1296 | 0.020 |
Why?
|
| Pedigree | 2 | 2006 | 4578 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 10343 | 0.020 |
Why?
|
| Testis | 1 | 2008 | 794 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 17790 | 0.020 |
Why?
|
| Luteinizing Hormone, beta Subunit | 1 | 2004 | 11 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, beta Subunit | 1 | 2004 | 58 | 0.010 |
Why?
|
| Inheritance Patterns | 1 | 2006 | 340 | 0.010 |
Why?
|
| Spermatozoa | 1 | 2008 | 631 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 2004 | 176 | 0.010 |
Why?
|
| Young Adult | 3 | 2021 | 58748 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2018 | 3959 | 0.010 |
Why?
|
| Prognosis | 2 | 2001 | 29661 | 0.010 |
Why?
|
| Cholesterol | 1 | 1993 | 2924 | 0.010 |
Why?
|
| Survivors | 1 | 1994 | 2375 | 0.010 |
Why?
|
| Genetic Variation | 2 | 2011 | 6552 | 0.010 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2004 | 155 | 0.010 |
Why?
|
| Organ Size | 1 | 2008 | 2254 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2013 | 80345 | 0.010 |
Why?
|
| Sleep | 1 | 1999 | 4750 | 0.010 |
Why?
|
| Diazoxide | 1 | 2002 | 52 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2004 | 239 | 0.010 |
Why?
|
| Breast | 1 | 2011 | 1963 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2001 | 15760 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 2001 | 4899 | 0.010 |
Why?
|
| Male | 12 | 2013 | 359718 | 0.010 |
Why?
|
| Androstenedione | 1 | 2001 | 131 | 0.010 |
Why?
|
| Macromolecular Substances | 2 | 1994 | 1433 | 0.010 |
Why?
|
| Recurrence | 1 | 2013 | 8483 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4716 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 1737 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2004 | 1130 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 1129 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1998 | 81 | 0.010 |
Why?
|
| Smell | 1 | 2001 | 259 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 36286 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 2001 | 626 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2010 | 3905 | 0.010 |
Why?
|
| Gene Expression | 1 | 2011 | 7587 | 0.010 |
Why?
|
| Half-Life | 1 | 1999 | 652 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2011 | 5961 | 0.010 |
Why?
|
| Neuroprotective Agents | 1 | 2004 | 961 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 1998 | 8985 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2001 | 54306 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 1788 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 2210 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 1628 | 0.010 |
Why?
|
| Risk Factors | 2 | 1993 | 74333 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 1902 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 8556 | 0.010 |
Why?
|
| Freezing | 1 | 1996 | 306 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 17624 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 7805 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 3682 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 21029 | 0.010 |
Why?
|
| Calibration | 1 | 1996 | 816 | 0.010 |
Why?
|
| Animals | 5 | 2011 | 167960 | 0.010 |
Why?
|
| Follistatin | 1 | 1994 | 137 | 0.010 |
Why?
|
| CHO Cells | 1 | 1996 | 1389 | 0.010 |
Why?
|
| Biological Assay | 1 | 1996 | 630 | 0.010 |
Why?
|
| Child | 1 | 2021 | 79799 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 2427 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 865 | 0.010 |
Why?
|
| Kinetics | 1 | 1999 | 6377 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1993 | 2186 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 2061 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 4286 | 0.010 |
Why?
|
| Glycopeptides | 1 | 1991 | 220 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 1996 | 14661 | 0.010 |
Why?
|
| Body Fluids | 1 | 1991 | 319 | 0.010 |
Why?
|
| Culture Media | 1 | 1991 | 900 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 24102 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2004 | 18955 | 0.000 |
Why?
|
| Equipment Contamination | 1 | 1989 | 179 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2011 | 41337 | 0.000 |
Why?
|
| Catheters, Indwelling | 1 | 1989 | 428 | 0.000 |
Why?
|
| Forearm | 1 | 1989 | 429 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1994 | 2208 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1993 | 5039 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1989 | 2235 | 0.000 |
Why?
|
| Mice | 1 | 2011 | 81209 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1992 | 6359 | 0.000 |
Why?
|
| Stroke | 1 | 2004 | 9952 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 6538 | 0.000 |
Why?
|
| Swine | 1 | 1991 | 5899 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1989 | 1403 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2004 | 23374 | 0.000 |
Why?
|
| United States | 1 | 2008 | 72448 | 0.000 |
Why?
|
| Bacteria | 1 | 1989 | 2199 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1991 | 4938 | 0.000 |
Why?
|
| Cell Line | 1 | 1991 | 15620 | 0.000 |
Why?
|
Concepts
(247)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(21)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_